Skip to Content

Stage 2 Core Measure 2

Next Measure Previous Measure


Objective: Generate and transmit permissible prescriptions electronically (eRx).
Measure: More than 50 percent of all permissible prescriptions, or all prescriptions, written by the EP are queried for a drug formulary and transmitted electronically using Certified EHR Technology.
Exclusion:

  1. Any EP who writes fewer than 100 permissible prescriptions during the EHR reporting period; or
  2. Any EP who does not have a pharmacy within their organization and there are no pharmacies that accept electronic prescriptions within 10 miles of the EP's practice location at the start of his or her EHR reporting period.

CMS Specification Sheet

TennCare Notes
This objective and measure aligns with Core Measure 4 from Stage 1. Note that in Stage 2 the threshold has increased to 50 percent from 40 percent with an additional specification. All prescriptions are now queried for a drug formulary, and implementing a drug formulary check was previously an option with Stage 1, Menu Measure 1. There are now two possible exclusions for this measure rather than Exclusion A available in Stage 1 for 2011 and 2012.

Federal Regulations Governing This Measure

CMS' Final Rule

§ 495.6(j)(2)(ii) see objective, measure and exclusion above

Standards and Certification Final Rule

§ 170.314(b)(3) Electronic prescribing. Enable a user to electronically create prescriptions and prescription related information for electronic transmission in accordance with:

  • The standard specified in § 170.205(b)(2); and
  • At a minimum, the version of the standard specified in § 170.207(d)(2).

Depending on the type of certification issued to the EHR technology, it will also have been certified to the certification criterion adopted at 45 CFR 170.314 (g)(1), (g)(2), or both, in order to assist in the calculation of this meaningful use measure.  

§ 170.205(b)(2) Electronic prescribing. NCPDP SCRIPT Version 10.6.

§170.207(d) Medications. RxNorm, a standardized nomenclature for clinical drugs produced by the United States National Library of Medicine, August 6, 2012 Release (incorporated by reference in § 170.299)